GLP1R and obesity disorder: In agreement, 1.2 mg of liraglutide was shown to prevent a weight loss–induced decrease in whole-body bone mineral content during 1 year after diet-induced weight loss in women with obesity.12 The finding that whole-body BMD, mostly reflecting cortical bone mass,51 increased with liraglutide, is in line with the observation of cortical osteopenia and fragility in GLP-1 receptor knockout mice.52,53 Interestingly, in the present study, exercise alone and in combination with liraglutide was associated with mostly preserved cortical bones (forearm) and more trabecular bones (hip and spine).